Results 181 to 190 of about 57,313 (205)

Pan-cyclin-dependent kinase inhibition is a potential treatment for adenoid cystic carcinoma that downregulates the MYB::NFIB fusion and induces tumor regression. [PDF]

Cancer Commun (Lond)
Huang J, Larsson P, Kakay Afshari M, Tejera Nevado P, Tešan Tomić T, Fehr A, Jäwert F, Stenman G, Andersson MK.   +8 more
europepmc   +1 more source

A simple cell-cycle control system in Marchantia polymorpha provides a framework for understanding plant cell proliferation. [PDF]

Plant Cell
Romani F, Bonter I, Rebmann M, Takahashi G, Guzman-Chavez F, De Batté F, Hirakawa Y, Haseloff J.   +7 more
europepmc   +1 more source

Frontiers in Cell-Cycle-Targeting Therapies: Addressing the Heterogeneity of the Cancer Cell Cycle. [PDF]

Cancers (Basel)
Ganesan IP, Kiyokawa H.
europepmc   +1 more source

Nephrotoxicity secondary to CDK 4/6 inhibitors in advanced breast cancer patients and its impact on survival. [PDF]

Ther Adv Med Oncol
Avci T, Altunbas AA, Sahbazlar M, Ekinci F, Erdogan AP.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy

Trends in Cell Biology, 2021
Benjamin Le Calve, Gerardo Ferbeyre, Volker Blank   +2 more
exaly  

Cytoplasmic division cycles without the nucleus and mitotic CDK/cyclin complexes

Cell, 2023
Miquel Rosas-Salvans, Sophie Dumont, Mustafa G Aydoḡan   +2 more
exaly  

Structural based investigation of novel pyrazole-thiazole Hybrids as dual CDK-1 and CDK-2 inhibitors for cancer chemotherapy

Molecular Simulation, 2022
Narva Deshwar Kushwaha, Babita Kushwaha, Francis Kayamba   +2 more
exaly  

An Overview of CDK Enzyme Inhibitors in Cancer Therapy

Current Cancer Drug Targets, 2023
Bannimath Gurupadayya, Honnavalli Yogish Kumar   +1 more
exaly